Median OS was 81.2 months; NSND showed a trend toward improved OS ( p = 0.083) and improved OS after age/sex adjustment (HR 0.64, 95% CI 0.42–0.98), but not after full clinicopathologic adjustment; DSS did not differ ( p = 0.59).
According to the size of the tumors, pT1 tumors show significantly lower peritumoral and intratumoral TIL levels than pT2 tumors (Wilcoxon-test p = 0.008 and p = 0.002, with global Kruskal–Wallis p -values of 0.043 and 0.018, respectively), whereas only borderline significant differences in the number of stromal TILs in different pT groups was observed (global Kruskal–Wallis p = 0.083, with a Wilcoxon-test p -value of 0.042 between pT1 and pT2 tumors) ( Figure S1B ).
Given this premise, they found a favorable trend for systemic treatment compared to RT in the inoperable group ( p = 0.083).
Although pCR rates were consistent with our current results, this study showed an unfavorable trend for CROSS compared to PF (MST 32.7 versus 16.7 months, respectively, p = 0.083).
WF-ORI imaging showed a trend towards an increase in ΔORR (i.e., treatment resistant) between control and FOLFOX-treated PDCOs ( p = 0.083; Figure 3 A).
Notably, the impact of PSMA PET-CT staging on BRFS was marginally significant in the univariate analysis (hazard ratio (HR) 0.428, p = 0.083, 95% confidence interval (CI) 0.159–1.150). 3.5.
Tumor samples with Periostin high FAP low PDGFR low SMA high just showed a trend for a worse overall survival ( n (low) = 15, n (high) = 16, p = 0.083, Figure 2 B).
The univariate analysis (see Supplementary Materials ) showed that the two variables, Vascular Invasion and Cribriform, were significantly associated with survival outcomes ( p < 0.05), while the variable Stage was marginally significant ( p = 0.084).
Although non-significant, the combination treatment showed a trend of improved DFS compared to the no-treatment control ( p = 0.084) ( Figure 5 B).
In our series, lymphocyte levels below 1000/mcl were associated with borderline significance with a lower LRPFS in the HPV-positive subgroup ( p = 0.084, results not shown).
Additional exploratory analyses showed a trend toward higher prevalence of TP53 pathway alterations in Hispanic/Latino EOCRC patients (OR = 2.13, p = 0.084) and identified sex-based disparities in treatment, with women being less likely than men to receive FOLFOX (OR = 0.845, p = 0.0138).
Histological type showed a trend toward significance, with squamous histology associated with a higher hazard than adenocarcinoma (HR = 2.58, 95% CI: 0.92–8.33; p = 0.0849).
In the whole group, the MMP2 rs7201 C variant conferred an increased risk of locoregional recurrence ( p log-rank = 0.025, HR 1.55, p = 0.037; Figure 1 I), while the association of TIMP2 rs7501477 T allele with poor LRFS was only marginally significant ( p log-rank = 0.068, HR 1.40, 95% confidence interval (CI) 0.95–2.07, p = 0.085.
Subgroup analysis revealed a positive trend in reflux symptom management in the WECARE group ( p = 0.0856).
Binary category analyses indicated a marginally significant relationship between TPM status and longer telomeres ( p = 0.086), and changes in expression of miR449a ( p = 0.157), HDAC4 ( p = 0.146) and HDAC9 ( p = 0.149).
Muscle Strength, Cardiorespiratory Fitness, and Resting Metabolic Rate No significant changes in chest press strength ( p = 0.745) or seated row strength ( p = 0.744) were observed; however, leg press strength approached significance ( p = 0.086) with a 6.1 kg increase reported across the home-based program ( Table 4 ).
In multivariate analysis (Wald test; Table 2 ), two variables (pN and TN subtype) remained significant, whereas the 70-gene signature tended towards significance ( p = 0.086), and the prognostic value of XIAP was maintained (HR = 1.67, 95%CI 1.20–2.31, p = 2.07 × 10 −3 , Wald test), suggesting independent prognostic value.
In the Revised T category, the five-year cumulative OSR of T2 and T3 showed marginally significant differences (40.6% vs. 26.9%; p = 0.087) ( Figure 1 c). 2.3.
Figure 5 B shows an increasing trend in mortality risk for primary tumor patients when mut_coding variants were present ( p = 0.087).
Here, CD3 density and PD-1 expression in both tumor areas (CT, IM) showed a significant impact on both DFS and OS (CD3: CT, p = 0.018/IM, p = 0.002 and PD-1: CT, p = 0.037/IM, p = 0.016, respectively), whilst PD-L1 expression showed a trend towards improved survival (PD-L1: CT, p = 0.087/IM, p = 0.078); with regard to CD8 density, only expression in the IM was associated with improved survival.
HBV viral factors were not significantly different among groups with or without recurrence, despite the presence of HBV genotype C, indicating a slight trend toward HCC recurrence ( p = 0.087).
Although 16S rRNA sequencing data showed a trend towards more non-aerobic bacteria in BIA-ALCL compared to the benign seromas, this difference did not reach statistical significance ( p = 0.087) ( Figure 6 ). 4.
For NAALADL2-AS2 a low expression at baseline showed a trend for shorter OS compared to a high expression, median time to OS 21.9 months (95% CI; 18.8–44.9) vs. 30.7 (95% CI; 27.6–43.4) ( p = 0.088) ( Figure 3 D). 3.2.4.
Regarding margin status, R0CRM− resection was achieved in 17 MP-positive cases (61.3%) and 15 MP-negative cases (88.2%), indicating a statistical trend ( p = 0.088). 3.4.
≥70 years) ( Supplementary Figure S2 ) showed a trend toward significance for OS ( p = 0.088), while no significant difference was observed for PFS ( p = 0.337).